Breaking CBD News: Pressure BioSciences (OTCQB: $PBIO) Upcoming Investor
Call to Discuss Recent Acquisition of Uncle Buds
Uncle Bud's 2024 Revenue Expected to Increase
3-Fold to Approximately $5 Million, Fueled by UltraShear Processed Nanoemulsion
Product Introductions and Exciting New Market Opportunities
SOUTH EASTON, Mass.
- February 1, 2024 (Investorideas.com Newswire) Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBIO" or the "Company"), a
pioneer in the development and distribution of broadly enabling pressure-based
instruments, consumables, and specialty process development and testing
services across global industries, including nutraceuticals, food and beverage,
health and wellness, cosmetics, biotherapeutics, and more, today announced that
the Company will host a teleconference to discuss the recent strategic
acquisition of natural health and wellness innovator Uncle Bud's
("UB") in an all-stock transaction. In particular, the Company will
discuss its current, in-process move to new, more efficient manufacturing
space; the integration plan of the Uncle Bud's team and product offerings into
PBIO; and the significant growth expected from new UltraShear processed
nanoemulsion products, which are expected to catapult the Company's total
revenue by 5X to about $10M in 2024.
Read this news, featuring PBIO in
full at https://www.investorideas.com/news/2024/cannabis/02011PBIO-Investor-Call-Recent-Acquisition-Uncle-Buds.asp
UltraShear CBD Body Revive Spray
All
Natural, Fast Acting, Plant Based, Preservative Free, Best-in-Class Nano CBD
Teleconference Information
- Format:
Company presentation followed by Q&A.
- Date:
Monday, February 5, 2024. 4:30pm ET (US).
- Call-in
Number: 888-267-2918 (code: 973092).
- Replay: PBIO.Replay.020524
Transaction Significance
- Transaction
is expected to be immediately accretive and a major accelerator to PBIO's
top line revenue growth.
- Combined
companies will be positioned to attract new growth investment, rapidly
strengthen the balance sheet, accelerate PBIO's path to profitability in
2024, and catalyze PBIO's drive to uplist to NASDAQ/NYSE in 2024.
- UB
leadership are experts in branding, spokesperson management, and
online/retail multimedia marketing.
- UB will
rapidly incorporate PBIO's best-in-class Nano-CBD into renowned and successful
CBD product lines.
- Senior
management of UB/PBIO plan a dozen new nanoemulsion products for
commercial release in 2024.
- UB
already markets and sells many products in health & wellness that
expand well beyond Hemp and CBD.
- UB
continues building ongoing partnership with multi-Grammy award-winning
Toni Braxton - highly successful marketing ambassador leaps to embrace
combined PBIO/UB as continuing spokesperson.
- UB
enjoys strong following for leading hemp and CBD products, in extensive
variety of high profile news outlets and magazines online over many
years: https://www.unclebudshemp.com/press/.
- UB
currently boasts 70+ products, 865K on-line members, and enviable sales
channels with leading large retailers.
Expected Financial Impact
- Acquisition
combines existing momentum and ready market execution power of Uncle
Bud's, with revolutionary product breakthroughs in absorption and speed of
action, enabled by PBIO's UltraShear nanoemulsions platform.
- PBIO forecasts
Uncle Bud's $1.6 million 2023 revenue tripling to approximately $5 million
in 2024.
- PBIO
forecasts a 5-fold catapult forward in total Company revenues to
approximately $10 million in 2024.
Transaction Terms
Please refer to the Form 8K filed on January 19, 2024.
About Uncle Bud's
Launched in 2018 with a trailblazing hemp-based
Pain Relief product, Uncle Bud's has rapidly captured an innovative leadership
role in the Hemp Seed Oil, Cannabidiol (CBD), and the broader Health &
Wellness industry. The Uncle Bud's brand is revered for its unwavering
commitment to domestic manufacturing excellence, setting benchmarks for its
organic, preservative-free, non-GMO standards and its ethical cruelty-free
practices. Uncle Bud's is dedicated to the highest-quality formulations and to
continuous improvement, guided by the latest scientific research and
development innovations - including the revolutionary performance breakthroughs
delivered by PBIO's patented UltraShear™ processing platform. Uncle Bud's
diverse product portfolio addresses an ever-broadening spectrum of consumer
needs, encompassing pain relief, sophisticated skincare solutions, personal
wellness and athletic recovery products, and specialized pet care items. Learn
More: www.unclebudshemp.com *
Follow On Social Media: @UncleBuds_Hemp.
Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a global leader in providing
innovative, broadly enabling, high pressure-based solutions for a range of industries,
including biotechnology, pharmaceutical, nutraceutical, cosmeceutical, and
agrochemical, as well as food and beverage manufacturing. Our products utilize
both constant and alternating pressure. Our patented enabling technology
platform, Pressure Cycling Technology (PCT), utilizes alternating cycles of
pressure to control bio-molecular interactions (such as cell lysis and
biomolecule extraction) safely and reproducibly. PCT-based products are
beginning to be widely used for biomarker and target discovery, drug design and
development, biotherapeutics characterization and quality control, soil &
plant biology, forensics, and counter-bioterrorism applications. We have
recently expanded our market opportunities with the acquisition of the BaroFold™
patented technology platform, allowing us to enter the bio-pharma contract
services and GMP manufacturing equipment sector. We have also developed the
scalable and high-efficiency pressure-based UltraShear Technology™
(UltraShear™) platform, which allows for the creation of stable nanoemulsions
of otherwise immiscible fluids. It also allows for the preparation of higher
quality, homogenized, extended shelf-life or room temperature-stable low-acid
liquid foods that cannot be effectively preserved using existing non-thermal
technologies. Our commitment to innovation and cutting-edge technology has
established PBIO as a leader in the high-pressure industry, providing unique
and effective solutions to our customers.
Forward Looking
Statements
This press release contains forward-looking
statements. These statements relate to future events or our future financial
performance and involve known and unknown risks, uncertainties and other
factors that may cause our or our industry's actual results, levels of
activity, performance, or achievements to be materially different from any
future results, levels of activity, performance or achievements expressed,
implied, or inferred by these forward-looking statements. In some cases, you
can identify forward-looking statements by terminology such as "may,"
"will," "should," "could," "would,"
"expects," "plans," "intends,"
"anticipates," "believes," estimates,"
"predicts," "projects," "potential" or
"continue" or the negative of such terms and other comparable
terminology. These statements are only predictions based on our current
expectations and projections about future events. You should not place undue
reliance on these statements. In evaluating these statements, you should
specifically consider various factors. Actual events or results may differ
materially. These and other factors may cause our actual results to differ
materially from any forward-looking statement. These risks, uncertainties, and
other factors include, but are not limited to, the risks and uncertainties
discussed under the heading "Risk Factors" in the Company's Annual
Report on Form 10-K for the year ended December 31, 2022, and other reports
filed by the Company from time to time with the SEC. The Company undertakes no
obligation to update any of the information included in this release, except as
otherwise required by law.
For more information about PBIO,
Uncle Bud's, and this press release, please click on the following website
links:
http://www.pressurebiosciences.com www.unclebudshemp.com
Please visit us on Facebook, LinkedIn, and Twitter.
Press Contacts
Richard T. Schumacher, President
& CEO (508) 230-1828 (T)
Jeffrey N. Peterson, Chairman (650) 812-8121 (T)
Bruno Schiavi, President, PBIO Consumer Products (508) 230-1828 (T)
Disclaimer/Disclosure: Investorideas.com is a digital publisher of
third party sourced news, articles and equity research as well as creates
original content, including video, interviews and articles. Original content
created by investorideas is protected by copyright laws other than syndication
rights. Our site does not make recommendations for purchases or sale of stocks,
services or products. Nothing on our sites should be construed as an offer or
solicitation to buy or sell products or securities. All investing involves risk
and possible losses. This site is currently compensated for news publication
and distribution, social media and marketing, content creation and more.
Disclosure: this news for Pressure BioSciences, Inc. (PBIO) is paid for content
on our site. Disclosure More
disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn
more about publishing your news release and our other news services on the
Investorideas.com newswire https://www.investorideas.com/News-Upload/
About Investorideas.com
https://www.investorideas.com/About/
Sign up for free stock news alerts at
Investorideas.com
https://www.investorideas.com/Resources/Newsletter.asp
No comments:
Post a Comment